ValuentumAd

Official PayPal Seal

Eli Lilly Puts Up Strong Second Quarter Results, Raises Outlook

publication date: Aug 9, 2024
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Image: Shares of Eli Lilly have been strong the past few years. 

Looking to 2024 full-year guidance, Eli Lilly raised its revenue expectations by $3 billion, upped its reported earnings per share guidance $2.05, to the range of $15.10-$15.60, and increased its non-GAAP earnings per share guidance by $2.60 to the range of $16.10-$16.60, above the consensus forecasts. We continue to like Eli Lilly’s product portfolio, particularly Mounjaro and Zepbound, and we include the Health Care Select Sector SPDR Fund, which includes Eli Lilly as its top weighting, in the Best Ideas Newsletter portfolio.


Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please login.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.